Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 2/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7347255 | 0.79 | MAPK1 (0.43) | RIPK2LCKKDRTGFBR1SMN1; SMN2 | |
| SCHEMBL20334823 | 0.78 | RET (0.38) | RIPK2KDRRETSRCPDPK1 | |
| SCHEMBL20334789 | 0.73 | RET (0.52) | RETSRCPDPK1MIF | |
| SCHEMBL25061778 | 0.70 | RET (0.35) | RIPK2LCKKDRTGFBR1RET | |
| SCHEMBL6195848 | 0.70 | PIK3CG (0.37) | SMN1; SMN2RECQL | |
| SCHEMBL27475909 | 0.70 | MAPK1 (0.41) | RIPK2LCKKDRTGFBR1SMN1; SMN2 | |
| SCHEMBL20551370 | 0.69 | MAPK1 (0.46) | SMN1; SMN2GRIA4 | |
| SCHEMBL6197798 | 0.69 | SRC (0.35) | SRCIKBKB | |
| SCHEMBL27492051 | 0.69 | PDPK1 (0.36) | RIPK2LCKKDRTGFBR1RET | |
| SCHEMBL20550727 | 0.68 | GAA (0.36) | GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0995751-B1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER (US) | 2005-06-29 | — | — | EP | disclosed |
| US-6407114-B1 | BENIGN PROSTATIC HYPERPLASIA, CARDIOVASCULAR, GASTROINTESTINAL AND RESPIRATORY DISORDER TREATMENT; ANTIASTHMATIC, ANTIALLERGEN, AND ANTIDIABETIC AGENTS | PFIZER INC. | 2002-06-18 | — | — | US | disclosed |
| EP-0995751-A2 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. (US) | 2000-04-26 | — | — | EP | disclosed |